Table 2 The clinicopathological features of patients with DLBCL
From: MiR-214 prevents the progression of diffuse large B-cell lymphoma by targeting PD-L1
Characteristic | Total number of patients | Expression of miR-214 | P value | |
|---|---|---|---|---|
|  | 15 | High (N = 7) | aLow (N = 8) |  |
Age (years) | Â | Â | Â | 0.447 |
  ≥ 55 | 8 (53.33%) | 3 | 5 |  |
 < 55 | 7 (46.67%) | 4 | 3 |  |
Gender | Â | Â | Â | 0.833 |
 Male | 9 (60.00%) | 4 | 5 |  |
 Female | 6 (40.00%) | 3 | 3 |  |
Tumor size (cm) | Â | Â | Â | 0.020 |
  ≥ 3 | 9 (60.00%) | 2 | 7 |  |
 < 3 | 6 (40.00%) | 5 | 1 |  |
Clinical stage | Â | Â | Â | 0.036 |
 I - II | 5 (33.33%) | 4 | 1 |  |
 III - IV | 10 (66.67%) | 2 | 7 |  |
bLDH | Â | Â | Â | 0.782 |
 High (≥ 300) | 8 (53.33%) | 4 | 4 |  |
 Low (<  300) | 7 (46.67%) | 3 | 4 |  |
cIPI | Â | Â | Â | 0.013 |
 Low (0–2) | 4 (26.67%) | 4 | 0 |  |
 High (≥ 3) | 11 (73.33%) | 3 | 8 |  |